Meridian Bioscience (VIVO) 10-Q 7 Feb 20 2020 Q1 Quarterly report Financial data

Cover Page

Cover Page - shares	3 Months Ended
	Dec. 31, 2019	Jan. 31, 2020
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Entity Interactive Data Current	Yes
Document Transition Report	false
Amendment Flag	false
Document Period End Date	Dec. 31, 2019
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q1
Entity Registrant Name	MERIDIAN BIOSCIENCE INC
Entity Central Index Key	0000794172
Entity File Number	0-14902
Entity Tax Identification Number	31-0888197
Entity Incorporation, State or Country Code	OH
Current Fiscal Year End Date	--09-30
Entity Current Reporting Status	Yes
Entity Shell Company	false
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Address, Address Line One	3471 River Hills Drive
Entity Address, City or Town	Cincinnati
Entity Address, State or Province	OH
Entity Address, Postal Zip Code	45244
City Area Code	513
Local Phone Number	271-3700
Trading Symbol	VIVO
Security Exchange Name	NASDAQ
Title of 12(b) Security	Common Stock
Entity Common Stock, Shares Outstanding		42,829,480

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Income Statement [Abstract]
NET REVENUES	$ 47,421	$ 51,480
COST OF SALES	19,981	19,908
GROSS PROFIT	27,440	31,572
OPERATING EXPENSES
Research and development	4,824	3,967
Selling and marketing	6,684	7,563
General and administrative	8,756	8,902
Change in fair value of contingent consideration obligation	1,187
Restructuring costs	275
Selected legal costs	320	589
Total operating expenses	22,046	21,021
OPERATING INCOME	5,394	10,551
OTHER INCOME (EXPENSE)
Interest income	111	149
Interest expense	(767)	(363)
Other, net	(712)	139
Total other expense	(1,368)	(75)
EARNINGS BEFORE INCOME TAXES	4,026	10,476
INCOME TAX PROVISION	1,199	2,370
NET EARNINGS	$ 2,827	$ 8,106
Earnings Per Share Data:
BASIC EARNINGS PER COMMON SHARE	$ 0.07	$ 0.19
DILUTED EARNINGS PER COMMON SHARE	$ 0.07	$ 0.19
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING - BASIC	42,789	42,446
EFFECT OF DILUTIVE STOCK OPTIONS AND RESTRICTED SHARE UNITS	149	459
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING - DILUTED	42,938	42,905
ANTI-DILUTIVE SECURITIES:
Common share options and restricted share units	1,407	684
DIVIDENDS DECLARED PER COMMON SHARE		$ 0.125

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income - USD ($) $ in Thousands	3 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Statement of Comprehensive Income [Abstract]
NET EARNINGS	$ 2,827	$ 8,106
Other comprehensive income (loss):
Foreign currency translation adjustment	2,768	(716)
Unrealized loss on cash flow hedge		(577)
Reclassification of gain on cash flow hedge	(77)
Income taxes related to items of other comprehensive income	19	145
Other comprehensive income (loss), net of tax	2,710	(1,148)
COMPREHENSIVE INCOME	$ 5,537	$ 6,958

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
CASH FLOWS FROM OPERATING ACTIVITIES
Net earnings	$ 2,827	$ 8,106
Non-cash items included in net earnings:
Depreciation of property, plant and equipment	1,218	1,253
Amortization of intangible assets	1,722	829
Stock-based compensation	788	1,670
Deferred income taxes	419	96
Change in accrued contingent consideration	1,187
Change in the following:
Accounts receivable	550	317
Inventories	(3,526)	(37)
Prepaid expenses and other current assets	1,434	539
Accounts payable and accrued expenses	(664)	(4,081)
Income taxes payable	(464)	991
Other, net	(203)	(197)
Net cash provided by operating activities	5,288	9,486
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of property, plant and equipment	(340)	(1,109)
Net cash used for investing activities	(340)	(1,109)
CASH FLOWS FROM FINANCING ACTIVITIES
Dividends paid		(5,301)
Payments on term loan		(1,125)
Proceeds from exercise of stock options		66
Net cash used for financing activities		(6,360)
Effect of Exchange Rate Changes on Cash and Equivalents and Restricted Cash	1,212	(257)
Net Increase in Cash and Equivalents and Restricted Cash	6,160	1,760
Cash and Equivalents and Restricted Cash at Beginning of Period	62,397	60,763
Cash and Equivalents and Restricted Cash at End of Period	68,557	62,523
Cash and Equivalents	$ 68,557	61,523
Restricted Cash		$ 1,000

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2019	Sep. 30, 2019
Current Assets:
Cash and equivalents	$ 68,557	$ 62,397
Accounts receivable, less allowances of $527 and $537, respectively	35,318	35,608
Inventories	42,827	39,617
Prepaid expenses and other current assets	5,730	7,139
Total current assets	152,432	144,761
Property, Plant and Equipment, at Cost:
Land	985	982
Buildings and improvements	31,928	31,904
Machinery, equipment and furniture	65,320	64,155
Construction in progress	943	522
Subtotal	99,176	97,563
Less: accumulated depreciation and amortization	68,681	66,996
Net property, plant and equipment	30,495	30,567
Other Assets:
Goodwill	89,958	89,241
Other intangible assets, net	58,586	60,243
Right-of-use assets	6,041
Deferred income taxes	132	156
Other assets	484	510
Total other assets	155,201	150,150
Total assets	338,128	325,478
Current Liabilities:
Accounts payable	7,932	7,238
Accrued employee compensation costs	6,401	7,938
Accrued interest expense	958	498
Current portion of acquisition consideration	13,653
Current operating lease obligations	1,333
Other accrued expenses	2,977	3,260
Income taxes payable	1,599	1,980
Total current liabilities	34,853	20,914
Non-Current Liabilities:
Acquisition consideration	19,736	32,202
Post-employment benefits	2,484	2,500
Long-term operating lease obligations	4,480
Long-term debt	75,824	75,824
Long-term income taxes payable	549	549
Deferred income taxes	2,910	2,522
Total non-current liabilities	105,983	113,597
Commitments and Contingencies
Shareholders' Equity:
Preferred stock, no par value; 1,000,000 shares authorized; none issued
Common shares, no par value; 71,000,000 shares authorized, 42,827,758 and 42,712,296 shares issued, respectively
Additional paid-in capital	133,622	132,834
Retained earnings	65,935	63,108
Accumulated other comprehensive loss	(2,265)	(4,975)
Total shareholders' equity	197,292	190,967
Total liabilities and shareholders' equity	$ 338,128	$ 325,478

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Dec. 31, 2019	Sep. 30, 2019
Statement of Financial Position [Abstract]
Allowances for accounts receivable	$ 527	$ 537
Preferred stock, par value
Preferred stock, shares authorized	1,000,000,000	1,000,000,000
Preferred stock, shares issued	0	0
Common stock, par value
Common stock, shares authorized	71,000,000	71,000,000
Common stock, shares issued	42,827,758	42,712,296

Consolidated Statements of Shar

Consolidated Statements of Shareholders' Equity - USD ($) $ in Thousands	Total	Common Shares Issued [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Accumulated Other Comprehensive Income (Loss) [Member]
Beginning balance at Sep. 30, 2018	$ 175,418		$ 129,193	$ 49,602	$ (3,377)
Beginning balance, Shares at Sep. 30, 2018		42,400,000
Cash dividends paid	(5,301)			(5,301)
Conversion of restricted share units and exercise of stock options	13		13
Conversion of restricted share units and exercise of stock options, Shares		89,000
Stock compensation expense	1,670		1,670
Net earnings	8,106			8,106
Foreign currency translation adjustment	(716)				(716)
Hedging activity, net of tax	(432)				(432)
Adoption of ASU | Accounting Standards Update 2014-09 [Member]	(116)			(116)
Ending balance at Dec. 31, 2018	178,642		130,876	52,291	(4,525)
Ending balance, Shares at Dec. 31, 2018		42,489,000
Beginning balance at Sep. 30, 2019	190,967		132,834	63,108	(4,975)
Beginning balance, Shares at Sep. 30, 2019		42,712,000
Conversion of restricted share units and exercise of stock options, Shares		116,000
Stock compensation expense	788		788
Net earnings	2,827			2,827
Foreign currency translation adjustment	2,768				2,768
Hedging activity, net of tax	(58)				(58)
Ending balance at Dec. 31, 2019	$ 197,292		$ 133,622	$ 65,935	$ (2,265)
Ending balance, Shares at Dec. 31, 2019		42,828,000

Consolidated Statements of Sh_2

Consolidated Statements of Shareholders' Equity (Parenthetical)	3 Months Ended
	Dec. 31, 2018$ / shares
Statement of Stockholders' Equity [Abstract]
Cash dividends per common share	$ 0.125

Basis of Presentation

Basis of Presentation	3 Months Ended
	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	1. Basis of Presentation The interim condensed consolidated financial statements are unaudited and are prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information, and the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted pursuant to such rules and regulations. In the opinion of Management, the interim financial statements include all normal adjustments and disclosures necessary to present fairly the Company’s financial position as of December 31, 2019, the results of its operations for the three - - 10-K.

Significant Accounting Policies

Significant Accounting Policies	3 Months Ended
	Dec. 31, 2019
Accounting Policies [Abstract]
Significant Accounting Policies	2. Significant Accounting Policies A summary of the Company’s significant accounting policies is included in Note 1 to the audited consolidated financial statements of the Company’s fiscal 201 9 10-K (a) Revenue Recognition – Revenue Disaggregation The following tables present our revenues disaggregated by major geographic region, major product platform and disease state (Diagnostics only): Revenue by Reportable Segment & Geographic Region Three Months Ended December 31, 2019 2018 Inc (Dec) Diagnostics- Americas $ $ (9 )% EMEA 6,500 5,802 12 % ROW 556 440 26 % Total Diagnostics 34,791 36,665 (5 )% Life Science- Americas 4,019 4,521 (11 )% EMEA 4,966 7,363 (33 )% ROW 3,645 2,931 24 % Total Life Science 12,630 14,815 (15 ) Consolidated $ 47,421 $ 51,480 (8 )% Three Months Ended December 31, 2019 2018 Inc (Dec) Diagnostics- Molecular assays $ 6,887 $ 7,231 (5 )% Immunoassays & blood chemistry assays 27,904 29,434 (5 )% Total Diagnostics $ 34,791 $ 36,665 (5 )% Life Science- Molecular reagents $ 5,357 $ 6,615 (19 )% Immunological reagents 7,273 8,200 (11 )% Total Life Science $ 12,630 $ 14,815 (15 ) Revenue by Disease State (Diagnostics only) Three Months Ended December 31, 2019 2018 Inc (Dec) Diagnostics- Gastrointestinal assays $ $ (14 )% Respiratory illness assays 7,749 7,981 (3 )% Blood chemistry assays 5,150 4,430 16 % Other 5,846 5,639 4 % Total Diagnostics $ 34,791 $ 36,665 (5 )% Revenue Policies Product Sales Revenue from contracts with customers is recognized in an amount that reflects the consideration we expect to receive in exchange for products when obligations under such contracts are satisfied. Revenue is generally recognized at a point-in-time Revenue is reduced in the period of sale for fees paid to distributors, which are inseparable from the distributor’s purchase of our product and for which we receive no goods or services in return. Revenue for the Diagnostics segment is reduced at the date of sale for product price adjustments payable to certain distributors under local contracts. Management estimates accruals for distributor price adjustments based on local contract terms, sales data provided by distributors, historical statistics, current trends, and other factors. Changes to the accruals are recorded in the period that they become known. Such accruals are netted against accounts receivable. Shipping and handling costs incurred after control of the product is transferred to our customers are treated as fulfillment costs and not a separate performance obligation. Our payment terms differ by jurisdiction and customer but payment is generally required in a term ranging from 30 to 90 days from the date of shipment or satisfaction of the performance obligation. Trade accounts receivable are recorded in the accompanying Consolidated Balance Sheets at invoiced amounts less provisions for distributor price adjustments under local contracts and doubtful accounts. The allowance for doubtful accounts represents our estimate of probable credit losses and is based on historical write-off non-payment. Practical Expedients and Exemptions Revenue is recognized net of any taxes collected from customers (sales tax, value added tax, etc.), which are subsequently remitted to government authorities. Our diagnostic assay products are generally not subject to a customer right of return except for product recall events under the rules and regulations of the Food and Drug Administration or equivalent agencies outside the United States. In this circumstance, the costs to replace affected products would be accrued at the time a loss was probable and estimable. We expense as incurred the costs to obtain contracts, as the amortization period would be one year or less. These costs, recorded within selling and marketing expense, include our internal sales force compensation programs and certain partner sales incentive programs, as we have determined that annual compensation is commensurate with annual selling activities. Reagent Rental Arrangements Certain of our Diagnostics segment’s product platforms require the use of instruments for the tests to be processed. In many cases, a customer is given use of the instrument provided they continue purchasing the associated tests, also referred to as “consumables” or “reagents”. If a customer stops purchasing the consumables, the instrument must be returned to us. Such arrangements are common practice in the diagnostics industry and are referred to as “Reagent Rentals”. Reagent Rentals may also include instrument related services such as a limited replacement warranty, training and installation. We concluded that the use of the instrument and related services (collectively known as “lease elements”) are not within the scope of Accounting Standards Update (“ASU”) No. 2014-09 2016-02, Leases non-lease non-lease For the portion of the transaction price allocated to the non-lease point-in-time Revenue allocated to the lease elements of these Reagent Rental arrangements totaled approximately $1,150 and $1,050 in the three months ended December 31, 2019 and 2018, respectively, and are included as part of net revenues in our Condensed Consolidated Statements of Operations. (b) Fair Value Measurements – Assets and liabilities are recorded at fair value in accordance with Accounting Standards Codification (“ASC”) 820-10, Fair Value Measurements and Disclosures 820-10 820-10 Assets and liabilities measured and reported at fair value are classified and disclosed in one of the following categories based on inputs: Level 1 Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities Level 2 Quoted prices in markets that are not active and financial instruments for which all significant inputs are observable, either directly or indirectly Level 3 Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable As described in Note 3 The following table provides information by level for financial assets and liabilities that are measured at fair value on a recurring basis, noting that there were no such items as of September 30, 2018: Fair Value Measurements Using Inputs Considered as Carrying Value Level 1 Level 2 Level 3 Contingent consideration - As of December 31, 2019 $ 28,389 $ — $ — $ 28,389 As of September 30, 2019 $ 27,202 $ — $ — $ 27,202 In connection with the acquisition of the business of GenePOC and as described up to inclu de earn-out include re-measured period, resulting in a value of $28,389 as of December 31, 2019. (c) Recent Accounting Pronouncements – Pronouncements Adopted On October 1, 2019, the Company adopted ASC 842, Leases right-of-use “Leasing Arrangements” non-lease (d) Reclassifications – Certain reclassifications have been made to the prior year financial statements to conform to the current year presentation. Such reclassifications had no impact on net earnings or shareholders’ equity.

Acquisition of Business of Gene

Acquisition of Business of GenePOC	3 Months Ended
	Dec. 31, 2019
Business Combinations [Abstract]
Acquisition of Business of GenePOC	3. Acquisition of Business of GenePOC On June 3, 2019, we acquired the business of GenePOC Inc. (“GenePOC”), a Quebec City, Quebec Province, Canada based provider of molecular diagnostic instruments and assays. The purchase agreement contemplates a maximum total consideration of up to $120,000, which was as of the acquisition date. Pursuant to the purchase agreement, the maximum consideration is comprised of the following (noting that the valuation values the contingent consideration identified in (ii) and (iii) below at an aggregate amount of $27,202 as of the acquisition date): (i) a $50,000 cash payment on June 3, 2019, subject to a working capital adjustment and a holdback of $5,000 to secure selling party’s performance of certain post-closing obligations; (ii) two $10,000 installments contingent upon the achievement of certain product development milestones if achieved by September 30, 2020 and March 31, 2021, respectively; and (iii) up to $50,000 of contingent consideration payable if certain financial performance targets are achieved during the twelve-month period ending September 30, 2022. The total of the holdback identified in (i) above and the currently estimated value of the contingent consideration identified in (ii) and (iii) above are reflected within the accompanying Condensed Consolidated Balance Sheets as of December 31, 2019 as follows: Current liabilities Reflects anticipated settlement of the first product milestone payment and the holdback amounts in the first quarter of fiscal 2021. Non-current liabilities Reflects anticipated settlement of the second product We utilized cash and equivalents on hand and proceeds drawn from our $125,000 revolving credit facility, to finance the acquisition. Proceeds from the credit facility were also utilized to repay and settle the outstanding principal and interest due on our term loan (see Note 9 our our Purchase Price Allocation The recognized amounts of identifiable assets acquired and liabilities assumed in the acquisition of the GenePOC business are as follows: June 3, Measurement June 3, Fair value of assets acquired - Accounts receivable $ 58 $ (1 ) $ 57 Inventories 1,617 (106 ) 1,511 Other current assets 77 7 84 Property, plant and equipment 1,520 (96 ) 1,424 Goodwill 34,482 100 34,582 Other intangible assets (estimated useful life): License agreement (10 years) 5,990 — 5,990 Technology (15 years) 34,040 96 34,136 Government grant (1.33 years) 800 — 800 78,584 — 78,584 Fair value of liabilities assumed - Accounts payable and accrued expenses 1,082 (24 ) 1,058 Total consideration paid (including contingent consideration originally estimated at $27,202) $ 77,502 $ 24 $ 77,526 Pro Forma Information The following table provides the unaudited consolidated pro forma results for the periods presented as if the business of GenePOC had been acquired as of the beginning of fiscal 2019. Pro forma results do not include the effect of any synergies anticipated to be achieved from the acquisition, and accordingly, are not necessarily indicative of the results that would have occurred if the acquisition had occurred on the date indicated or that may result in the future. Three Months Ended December 31, 2019 2018 Net Revenues $ 47,421 $ 51,552 Net Earnings $ 2,827 $ 4,379 These pro forma amounts have been calculated by including the results of GenePOC, and adjusting the combined results to give effect to the following, as if the acquisition had been consummated on October 1, 2018, together with the consequential tax effects thereon: Three Months Ended December 31, 2019 2018 Adjustments to Net Revenues GenePOC pre-acquisition $ — $ 72 Adjustments to Net Earnings GenePOC pre-acquisition $ — $ (3,203 ) Pro forma adjustments: Expenses related to non-continuing locations or activities — 568 Incremental depreciation and amortization — (876 ) Incremental interest costs — (284 ) Tax effects of pro forma adjustments — 68 Total Adjustments to Net Earnings $ — $ (3,727 )

Restructuring

Restructuring	3 Months Ended
	Dec. 31, 2019
Restructuring and Related Activities [Abstract]
Restructuring	4. Restructuring During the second quarter of fiscal 2018, the Company began implementation of a plan to realign its business structure into two business units, Diagnostics and Life Science, supported by a global corporate team. Since that time and as part of this plan, certain functions and locations within both business units have been streamlined, including: (i) the elimination of certain executive management and commercial sales positions; (ii) the closing of Life Science locations in Taunton, Massachusetts and Singapore, the operations of which were transferred to our locations in Memphis, Tennessee and London, England, respectively; and (iii) the transfer of certain functions performed in the Billerica, Massachusetts Diagnostics facility to the corporate headquarters in Cincinnati, Ohio. Further restructuring costs were incurred in fiscal 2019 and the first quarter of fiscal 2020, as refinements to each business unit’s cost structure continued to be made and the Company incurred severance payment obligations relating to the transition of its previous chief financial officer. As a result of these activities, restructuring costs totaling $ 275 2,839 and the fiscal year ended September 30, 2019, respectively. A reconciliation of the changes in the liabilities associated with the restructuring charges from September 30, 2019 through December 31, 2019 is as follows: Employee Lease and Other Total Balance at September 30, 2019 $ 1,010 $ 12 114 $ 1,136 Restructuring charges 236 80 — 316 Reversal of prior period accruals (41 ) — — (41 ) Payments (1,020 ) (65 ) (114 ) (1,199 ) Balance at December 31, 2019 $ 185 $ 27 $ — $ 212

Cash and Equivalents

Cash and Equivalents	3 Months Ended
	Dec. 31, 2019
Cash and Cash Equivalents [Abstract]
Cash and cash equivalents disclosure [TextBlock]	5. Cash and Equivalents Cash and equivalents include the following: December 31, September 30, Institutional money market funds $ 21,010 $ 20,913 Cash on hand, unrestricted 47,547 41,484 Total $ 68,557 $ 62,397

Inventories

Inventories	3 Months Ended
	Dec. 31, 2019
Inventory Disclosure [Abstract]
Inventories	6. Inventories Inventories are comprised of the following: December 31, September 30, Raw materials $ 8,549 $ 7,455 Work-in-process 12,209 11,504 Finished goods - instruments 688 935 Finished goods - kits and reagents 21,381 19,723 Total $ 42,827 $ 39,617

Leasing Arrangements

Leasing Arrangements	3 Months Ended
	Dec. 31, 2019
Leases [Abstract]
Leasing Arrangements	7. Leasing Arrangements The Company is party to a number of operating leases, the majority of which are related to office, warehouse and manufacturing space. The related operating lease assets and obligations are reflected within right-of-us e operating costs In addition, the Company has periodically entered into other short-term operating leases, generally with an initial term of twelve months or less. These leases are not recorded on the balance sheet and the related lease expense is immaterial for the three months ended December 31, 2019. The Company often has options to renew lease terms, with the exercise of lease renewal options generally at the Company’s sole discretion. In addition, certain lease arrangements may be terminated prior to their original expiration date at our discretion. We evaluate renewal and termination options at the lease commencement date to determine if we are reasonably certain to exercise the option on the basis of economic factors. The weighted average remaining lease term for our operating lease s as of December 31, 2019 was 4.7 years The discount rate implicit within our leases is generally not determinable and, therefore, the Company determines the discount rate on its incremental borrowing rate. The weighted average discount rate used to measure our operating leases as of December 31, 2019 was 3.7% Supplemental cash flow information related to the Company’s operating leases are as follows: Three Months Ended December 31, 2019 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 387 Maturities of lease liabilities by fiscal year for the Company’s operating lease liabilities were as follows as of December 31, 2019: December 31, Remainder of 2020 $ 1,132 2021 1,456 2022 1,310 2023 967 2024 712 Thereafter 616 Total lease payments 6,193 Less amount of lease payment representing interest (380 ) Total present value of lease payments $ 5,813 As of September 30, 2019, future minimum lease payments under noncancelable operating leases were as follows: September 30, 2020 $ 1,528 2021 1,451 2022 1,293 2023 967 2024 712 Thereafter 616 Total $ 6,567

Intangible Assets

Intangible Assets	3 Months Ended
	Dec. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	8. Intangible Assets A summary of our acquired intangible assets subject to amortization is as follows: December 31, 2019 September 30, 2019 Gross Accumulated Gross Accumulated Manufacturing technologies, core products and cell lines $ 56,273 $ 16,057 $ 56,193 $ 15,096 Trade names, licenses and patents 14,596 6,566 14,494 6,094 Customer lists, customer relationships and supply agreements 24,500 14,626 24,274 14,110 Government grants 828 362 814 232 Total $ 96,197 $ 37,611 $ 95,775 $ 35,532

Bank Credit Arrangements

Bank Credit Arrangements	3 Months Ended
	Dec. 31, 2019
Debt Disclosure [Abstract]
Bank Credit Arrangements	9. Bank Credit Arrangements In anticipation of the acquisition of the business of GenePOC (see Note 3), on May 24, 2019 the Company entered into a credit facility agreement with a commercial bank. The credit facility, which expires in May 2024, makes available to the Company a revolving credit facility in an aggregate principal amount not to exceed $125,000, with outstanding principal amounts bearing interest at a fluctuating rate tied to, at the Company’s option, either the federal funds rate or LIBOR, resulting in an effective interest rate of 3.96% on the credit facility during the three months ended December 31, 2019. To date, five on-hand, The revolving credit facility is collateralized by the business assets of the Company’s U.S. subsidiaries and requires compliance with financial covenants that limit the amount of debt obligations and require a minimum level of coverage of fixed charges, as defined in the credit facility agreement. As of December 31, 2019, the Company is in compliance with all covenants. In connection with the term loan repayment, the Company also settled the interest rate swap that had been entered into to limit exposure to volatility in the term loan’s LIBOR interest rate. At the time of settlement, the Company received a cash payment in an amount equal to the $563 then-current fair value of the interest rate swap. Accordingly, there is no balance for the interest rate swap reflected within assets or liabilities within the accompanying Consolidated Balance Sheet s

Reportable Segment and Major Cu

Reportable Segment and Major Customers Information	3 Months Ended
	Dec. 31, 2019
Segment Reporting [Abstract]
Reportable Segments and Major Concentration Data	10 Reportable Segment and Major Customers Information Meridian was formed in 1976 and functions as a fully-integrated life science company with principal businesses in: (i) the development, manufacture, sale and distribution of diagnostic test kits, primarily for certain gastrointestinal and respiratory infectious diseases, and elevated blood lead levels; and (ii) the manufacture and distribution of bulk antigens, antibodies, PCR/qPCR reagents, nucleotides, and bioresearch reagents used by researchers and other diagnostic manufacturers. Our reportable segments are Diagnostics and Life Science. The Diagnostics segment consists of manufacturing operations for infectious disease products in Cincinnati, Ohio and Quebec City, Canada, manufacturing operations for blood chemistry products in Billerica, Massachusetts (near Boston), and the sale and distribution of diagnostics products domestically and abroad. This segment’s products are used by hospitals, reference labs and physician offices to detect infectious diseases and elevated lead levels in blood. The Life Science segment consists of manufacturing operations in Memphis, Tennessee; Boca Raton, Florida; London, England; and Luckenwalde, Germany, and the sale and distribution of bulk antigens, antibodies, PCR/qPCR reagents, nucleotides, and bioresearch reagents domestically and abroad, including a sales and business development facility in Beijing, China to further pursue revenue opportunities in Asia. This segment’s products are used by manufacturers and researchers in a variety of applications (e.g., in-vitro next-gen Amounts due from two Diagnostics distributor customers accounted for 21% and 13% of consolidated accounts receivable at December 31, 2019 and September 30, 2019, respectively. Revenues from these two distributor customers accounted for 28% and 34% of the Diagnostics segment third-party revenues during the three months ended December 31, 2019 and 2018, respectively, and represented 20% and 24% of consolidated revenues for the fiscal 2020 and 2019 first quarters, respectively. Within our Life Science segment, two IVD Segment information for the interim periods is as follows: Diagnostics Life Science Corporate (1) Eliminations (2) Total Three Months Ended December 31, 2019 Net revenues - Third- p $ 34,791 $ 12,630 $ — $ — $ 47,421 Inter-segment 97 65 — (162 ) — Operating income 4,408 3,061 (2,087 ) 12 5,394 Goodwill (December 31, 2019) 70,415 19,543 — — 89,958 Other intangible assets, net (December 31, 2019) 58,277 309 — — 58,586 Total assets (December 31, 2019) 266,514 72,081 — (467 ) 338,128 Three Months Ended December 31, 2018 Net revenues - Third- p $ 36,665 $ 14,815 $ — $ — $ 51,480 Inter-segment 163 176 — (339 ) — Operating income 8,786 5,129 (3,391 ) 27 10,551 Goodwill (September 30, 2019) 70,395 18,846 — — 89,241 Other intangible assets, net (September 30, 2019) 59,807 436 — — 60,243 Total assets (September 30, 2019) 255,169 70,392 — (83 ) 325,478 (1) Includes Restructuring Cost s (2) Eliminations consist of inter-segment transactions. A reconciliation of segment operating income to consolidated earnings before income taxes for the three months ended December 31, 2019 and 2018 is as follows: Three Months Ended December 31, 2019 2018 Segment operating income $ 7,481 $ 13,942 Corporate expenses (2,087 ) (3,391 ) Interest income 111 149 Interest expense (767 ) (363 ) Other, net (712 ) 139 Consolidated earnings before income taxes $ 4,026 $ 10,476 Transactions between segments are accounted for at established intercompany prices for internal and management purposes, with all intercompany amounts eliminated in consolidation.

Litigation Matters

Litigation Matters	3 Months Ended
	Dec. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
Litigation Matters	1 1 Litigation Matters On November 15, 2017, Barbara Forman filed a class action complaint in the United States District Court for the Southern District of Ohio (the Court) naming Meridian, its former Chief Executive Officer and former Chief Financial Officer (in their capacities as such) as defendants. An amended complaint was filed on April 16, 2018 and the Company believes the essential elements of the amended complaint are the same. On July 9, 2019, a settlement was reached with the plaintiff that provides for a $2,100 d o d o On December 6, 2017, Michael Edelson filed a derivative complaint in the United States District Court for the Southern District of Ohio naming Meridian, its former Chief Executive Officer, former Chief Financial Officer and certain members of Meridian’s Board of Directors and Audit Committee (in their capacities as such) as defendants. The complaint alleges that Meridian made false and misleading representations concerning certain of Magellan’s lead test systems at or around the time of Meridian’s acquisition of Magellan and subsequent thereto, and the complaint alleges that certain members of the Board of Directors and Audit Committee breached their fiduciary duties in their oversight of the Company’s public disclosures and corporate governance matters. The complaint sought compensatory damages, equitable relief relating to corporate governance matters and attorneys’ fees. On October 9, 2019, the On April 17, 2018, Meridian’s wholly-owned subsidiary, Magellan Diagnostics, Inc. received a subpoena from the United States Department of Justice (“DOJ”) regarding its LeadCare product line. The subpoena outlines documents to be produced, and the Company is cooperating with the DOJ in this matter. The Company maintains rigorous policies and procedures to promote compliance with applicable regulatory agencies and requirements, and is working with the DOJ to promptly respond to the subpoena, including responding to additional information requests. The Company has executed tolling agreements to extend the statute of limitations. The Company cannot predict when the investigation will be resolved, the outcome of the investigation, or its potential impact on the Company. Approximately $ 280 and $540 of expense for attorneys’ fees related to this matter is included within the accompanying Condensed Consolidated Statements of Operations for the three months ended December 31 , 2019 and December 31 , 2018 , respectively.

Significant Accounting Polici_2

Significant Accounting Policies (Policies)	3 Months Ended
	Dec. 31, 2019
Accounting Policies [Abstract]
Revenue Recognition	(a) Revenue Recognition – Revenue Disaggregation The following tables present our revenues disaggregated by major geographic region, major product platform and disease state (Diagnostics only): Revenue by Reportable Segment & Geographic Region Three Months Ended December 31, 2019 2018 Inc (Dec) Diagnostics- Americas $ $ (9 )% EMEA 6,500 5,802 12 % ROW 556 440 26 % Total Diagnostics 34,791 36,665 (5 )% Life Science- Americas 4,019 4,521 (11 )% EMEA 4,966 7,363 (33 )% ROW 3,645 2,931 24 % Total Life Science 12,630 14,815 (15 ) Consolidated $ 47,421 $ 51,480 (8 )% Three Months Ended December 31, 2019 2018 Inc (Dec) Diagnostics- Molecular assays $ 6,887 $ 7,231 (5 )% Immunoassays & blood chemistry assays 27,904 29,434 (5 )% Total Diagnostics $ 34,791 $ 36,665 (5 )% Life Science- Molecular reagents $ 5,357 $ 6,615 (19 )% Immunological reagents 7,273 8,200 (11 )% Total Life Science $ 12,630 $ 14,815 (15 ) Revenue by Disease State (Diagnostics only) Three Months Ended December 31, 2019 2018 Inc (Dec) Diagnostics- Gastrointestinal assays $ $ (14 )% Respiratory illness assays 7,749 7,981 (3 )% Blood chemistry assays 5,150 4,430 16 % Other 5,846 5,639 4 % Total Diagnostics $ 34,791 $ 36,665 (5 )% Revenue Policies Product Sales Revenue from contracts with customers is recognized in an amount that reflects the consideration we expect to receive in exchange for products when obligations under such contracts are satisfied. Revenue is generally recognized at a point-in-time Revenue is reduced in the period of sale for fees paid to distributors, which are inseparable from the distributor’s purchase of our product and for which we receive no goods or services in return. Revenue for the Diagnostics segment is reduced at the date of sale for product price adjustments payable to certain distributors under local contracts. Management estimates accruals for distributor price adjustments based on local contract terms, sales data provided by distributors, historical statistics, current trends, and other factors. Changes to the accruals are recorded in the period that they become known. Such accruals are netted against accounts receivable. Shipping and handling costs incurred after control of the product is transferred to our customers are treated as fulfillment costs and not a separate performance obligation. Our payment terms differ by jurisdiction and customer but payment is generally required in a term ranging from 30 to 90 days from the date of shipment or satisfaction of the performance obligation. Trade accounts receivable are recorded in the accompanying Consolidated Balance Sheets at invoiced amounts less provisions for distributor price adjustments under local contracts and doubtful accounts. The allowance for doubtful accounts represents our estimate of probable credit losses and is based on historical write-off non-payment. Practical Expedients and Exemptions Revenue is recognized net of any taxes collected from customers (sales tax, value added tax, etc.), which are subsequently remitted to government authorities. Our diagnostic assay products are generally not subject to a customer right of return except for product recall events under the rules and regulations of the Food and Drug Administration or equivalent agencies outside the United States. In this circumstance, the costs to replace affected products would be accrued at the time a loss was probable and estimable. We expense as incurred the costs to obtain contracts, as the amortization period would be one year or less. These costs, recorded within selling and marketing expense, include our internal sales force compensation programs and certain partner sales incentive programs, as we have determined that annual compensation is commensurate with annual selling activities. Reagent Rental Arrangements Certain of our Diagnostics segment’s product platforms require the use of instruments for the tests to be processed. In many cases, a customer is given use of the instrument provided they continue purchasing the associated tests, also referred to as “consumables” or “reagents”. If a customer stops purchasing the consumables, the instrument must be returned to us. Such arrangements are common practice in the diagnostics industry and are referred to as “Reagent Rentals”. Reagent Rentals may also include instrument related services such as a limited replacement warranty, training and installation. We concluded that the use of the instrument and related services (collectively known as “lease elements”) are not within the scope of Accounting Standards Update (“ASU”) No. 2014-09 2016-02, Leases non-lease non-lease For the portion of the transaction price allocated to the non-lease point-in-time Revenue allocated to the lease elements of these Reagent Rental arrangements totaled approximately $1,150 and $1,050 in the three months ended December 31, 2019 and 2018, respectively, and are included as part of net revenues in our Condensed Consolidated Statements of Operations.
Fair Value Measurements	(b) Fair Value Measurements – Assets and liabilities are recorded at fair value in accordance with Accounting Standards Codification (“ASC”) 820-10, Fair Value Measurements and Disclosures 820-10 820-10 Assets and liabilities measured and reported at fair value are classified and disclosed in one of the following categories based on inputs: Level 1 Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities Level 2 Quoted prices in markets that are not active and financial instruments for which all significant inputs are observable, either directly or indirectly Level 3 Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable As described in Note 3 The following table provides information by level for financial assets and liabilities that are measured at fair value on a recurring basis, noting that there were no such items as of September 30, 2018: Fair Value Measurements Using Inputs Considered as Carrying Value Level 1 Level 2 Level 3 Contingent consideration - As of December 31, 2019 $ 28,389 $ — $ — $ 28,389 As of September 30, 2019 $ 27,202 $ — $ — $ 27,202 In connection with the acquisition of the business of GenePOC and as described up to inclu de earn-out include re-measured period, resulting in a value of $28,389 as of December 31, 2019.
Recent Accounting Pronouncements	(c) Recent Accounting Pronouncements – Pronouncements Adopted On October 1, 2019, the Company adopted ASC 842, Leases right-of-use “Leasing Arrangements” non-lease
Reclassifications	(d) Reclassifications – Certain reclassifications have been made to the prior year financial statements to conform to the current year presentation. Such reclassifications had no impact on net earnings or shareholders’ equity.

Significant Accounting Polici_3

Significant Accounting Policies (Tables)	3 Months Ended
	Dec. 31, 2019
Accounting Policies [Abstract]
Summary of Disaggregation of Revenue	The following tables present our revenues disaggregated by major geographic region, major product platform and disease state (Diagnostics only): Revenue by Reportable Segment & Geographic Region Three Months Ended December 31, 2019 2018 Inc (Dec) Diagnostics- Americas $ $ (9 )% EMEA 6,500 5,802 12 % ROW 556 440 26 % Total Diagnostics 34,791 36,665 (5 )% Life Science- Americas 4,019 4,521 (11 )% EMEA 4,966 7,363 (33 )% ROW 3,645 2,931 24 % Total Life Science 12,630 14,815 (15 ) Consolidated $ 47,421 $ 51,480 (8 )% Three Months Ended December 31, 2019 2018 Inc (Dec) Diagnostics- Molecular assays $ 6,887 $ 7,231 (5 )% Immunoassays & blood chemistry assays 27,904 29,434 (5 )% Total Diagnostics $ 34,791 $ 36,665 (5 )% Life Science- Molecular reagents $ 5,357 $ 6,615 (19 )% Immunological reagents 7,273 8,200 (11 )% Total Life Science $ 12,630 $ 14,815 (15 ) Revenue by Disease State (Diagnostics only) Three Months Ended December 31, 2019 2018 Inc (Dec) Diagnostics- Gastrointestinal assays $ $ (14 )% Respiratory illness assays 7,749 7,981 (3 )% Blood chemistry assays 5,150 4,430 16 % Other 5,846 5,639 4 % Total Diagnostics $ 34,791 $ 36,665 (5 )%
Summary of Fair Value, Assets and Liabilities Measured on Recurring Basis	The following table provides information by level for financial assets and liabilities that are measured at fair value on a recurring basis, noting that there were no such items as of September 30, 2018: Fair Value Measurements Using Inputs Considered as Carrying Value Level 1 Level 2 Level 3 Contingent consideration - As of December 31, 2019 $ 28,389 $ — $ — $ 28,389 As of September 30, 2019 $ 27,202 $ — $ — $ 27,202

Acquisition of Business of Ge_2

Acquisition of Business of GenePOC (Tables)	3 Months Ended
	Dec. 31, 2019
Business Combinations [Abstract]
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed	The recognized amounts of identifiable assets acquired and liabilities assumed in the acquisition of the GenePOC business are as follows: June 3, Measurement June 3, Fair value of assets acquired - Accounts receivable $ 58 $ (1 ) $ 57 Inventories 1,617 (106 ) 1,511 Other current assets 77 7 84 Property, plant and equipment 1,520 (96 ) 1,424 Goodwill 34,482 100 34,582 Other intangible assets (estimated useful life): License agreement (10 years) 5,990 — 5,990 Technology (15 years) 34,040 96 34,136 Government grant (1.33 years) 800 — 800 78,584 — 78,584 Fair value of liabilities assumed - Accounts payable and accrued expenses 1,082 (24 ) 1,058 Total consideration paid (including contingent consideration originally estimated at $27,202) $ 77,502 $ 24 $ 77,526
Business Acquisition, Pro Forma Information	Three Months Ended December 31, 2019 2018 Net Revenues $ 47,421 $ 51,552 Net Earnings $ 2,827 $ 4,379
Business Acquisition Proforma Adjustments	These pro forma amounts have been calculated by including the results of GenePOC, and adjusting the combined results to give effect to the following, as if the acquisition had been consummated on October 1, 2018, together with the consequential tax effects thereon: Three Months Ended December 31, 2019 2018 Adjustments to Net Revenues GenePOC pre-acquisition $ — $ 72 Adjustments to Net Earnings GenePOC pre-acquisition $ — $ (3,203 ) Pro forma adjustments: Expenses related to non-continuing locations or activities — 568 Incremental depreciation and amortization — (876 ) Incremental interest costs — (284 ) Tax effects of pro forma adjustments — 68 Total Adjustments to Net Earnings $ — $ (3,727 )

Restructuring (Tables)

Restructuring (Tables)	3 Months Ended
	Dec. 31, 2019
Restructuring and Related Activities [Abstract]
Summary of Restructuring Costs	A reconciliation of the changes in the liabilities associated with the restructuring charges from September 30, 2019 through December 31, 2019 is as follows: Employee Lease and Other Total Balance at September 30, 2019 $ 1,010 $ 12 114 $ 1,136 Restructuring charges 236 80 — 316 Reversal of prior period accruals (41 ) — — (41 ) Payments (1,020 ) (65 ) (114 ) (1,199 ) Balance at December 31, 2019 $ 185 $ 27 $ — $ 212

Cash and Equivalents (Tables)

Cash and Equivalents (Tables)	3 Months Ended
	Dec. 31, 2019
Cash and Cash Equivalents [Abstract]
Components of Cash and Cash Equivalents	Cash and equivalents include the following: December 31, September 30, Institutional money market funds $ 21,010 $ 20,913 Cash on hand, unrestricted 47,547 41,484 Total $ 68,557 $ 62,397

Inventories (Tables)

Inventories (Tables)	3 Months Ended
	Dec. 31, 2019
Inventory Disclosure [Abstract]
Components of Inventories	Inventories are comprised of the following: December 31, September 30, Raw materials $ 8,549 $ 7,455 Work-in-process 12,209 11,504 Finished goods - instruments 688 935 Finished goods - kits and reagents 21,381 19,723 Total $ 42,827 $ 39,617

Leasing Arrangements (Tables)

Leasing Arrangements (Tables)	3 Months Ended
	Dec. 31, 2019
Leases [Abstract]
Schedule Of Supplemental Cash Flow Information Related To The CompanyS Operating Lease Liabilities	Supplemental cash flow information related to the Company’s operating leases are as follows: Three Months Ended December 31, 2019 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 387
Schedule of maturities of lease liabilities	Maturities of lease liabilities by fiscal year for the Company’s operating lease liabilities were as follows as of December 31, 2019: December 31, Remainder of 2020 $ 1,132 2021 1,456 2022 1,310 2023 967 2024 712 Thereafter 616 Total lease payments 6,193 Less amount of lease payment representing interest (380 ) Total present value of lease payments $ 5,813 As of September 30, 2019, future minimum lease payments under noncancelable operating leases were as follows: September 30, 2020 $ 1,528 2021 1,451 2022 1,293 2023 967 2024 712 Thereafter 616 Total $ 6,567

Intangible Assets (Tables)

Intangible Assets (Tables)	3 Months Ended
	Dec. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Summary of Acquired Intangible Assets Subject to Amortization	A summary of our acquired intangible assets subject to amortization is as follows: December 31, 2019 September 30, 2019 Gross Accumulated Gross Accumulated Manufacturing technologies, core products and cell lines $ 56,273 $ 16,057 $ 56,193 $ 15,096 Trade names, licenses and patents 14,596 6,566 14,494 6,094 Customer lists, customer relationships and supply agreements 24,500 14,626 24,274 14,110 Government grants 828 362 814 232 Total $ 96,197 $ 37,611 $ 95,775 $ 35,532

Reportable Segment and Major _2

Reportable Segment and Major Customers Information (Tables)	3 Months Ended
	Dec. 31, 2019
Segment Reporting [Abstract]
Segment Information	Segment information for the interim periods is as follows: Diagnostics Life Science Corporate (1) Eliminations (2) Total Three Months Ended December 31, 2019 Net revenues - Third- p $ 34,791 $ 12,630 $ — $ — $ 47,421 Inter-segment 97 65 — (162 ) — Operating income 4,408 3,061 (2,087 ) 12 5,394 Goodwill (December 31, 2019) 70,415 19,543 — — 89,958 Other intangible assets, net (December 31, 2019) 58,277 309 — — 58,586 Total assets (December 31, 2019) 266,514 72,081 — (467 ) 338,128 Three Months Ended December 31, 2018 Net revenues - Third- p $ 36,665 $ 14,815 $ — $ — $ 51,480 Inter-segment 163 176 — (339 ) — Operating income 8,786 5,129 (3,391 ) 27 10,551 Goodwill (September 30, 2019) 70,395 18,846 — — 89,241 Other intangible assets, net (September 30, 2019) 59,807 436 — — 60,243 Total assets (September 30, 2019) 255,169 70,392 — (83 ) 325,478 (1) Includes Restructuring Cost s (2) Eliminations consist of inter-segment transactions.
Pre-tax Earnings Table	A reconciliation of segment operating income to consolidated earnings before income taxes for the three months ended December 31, 2019 and 2018 is as follows: Three Months Ended December 31, 2019 2018 Segment operating income $ 7,481 $ 13,942 Corporate expenses (2,087 ) (3,391 ) Interest income 111 149 Interest expense (767 ) (363 ) Other, net (712 ) 139 Consolidated earnings before income taxes $ 4,026 $ 10,476

Significant Accounting Polici_4

Significant Accounting Policies - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Oct. 01, 2019	Jun. 03, 2019
Schedule Of Accounting Policies [Line Items]
Revenue, description of payment terms	30 to 90 days from the date of shipment or satisfaction of the performance obligation
Contingent consideration liability	$ 28,389			$ 27,202
Right-of-use assets	6,041
Lease obligations	5,813
Revenues	47,421	$ 51,480
Reagent Rental Arrangements [Member] | Lease Elements [Member] | Revenues [Member]
Schedule Of Accounting Policies [Line Items]
Revenues	$ 1,150	$ 1,050
ASU 2016-02 [Member]
Schedule Of Accounting Policies [Line Items]
Right-of-use assets			$ 5,880
Lease obligations			$ 5,880
Maximum [Member]
Schedule Of Accounting Policies [Line Items]
Contract cost, amortization period	1 year
Maximum [Member] | Financial Performance Targets [Member]
Schedule Of Accounting Policies [Line Items]
Potential milestone payment	$ 50,000
GenePOC
Schedule Of Accounting Policies [Line Items]
Contingent consideration liability				$ 27,202
GenePOC | Maximum [Member] | Product Development Milestones [Member]
Schedule Of Accounting Policies [Line Items]
Potential milestone payment	20,000
GenePOC | Maximum [Member] | Financial Performance Targets [Member]
Schedule Of Accounting Policies [Line Items]
Potential milestone payment	50,000
GenePOC | Maximum [Member] | Product Development Milestones And Financial Performance Targets [Member]
Schedule Of Accounting Policies [Line Items]
Potential milestone payment	$ 70,000

Significant Accounting Polici_5

Significant Accounting Policies - Summary of Disaggregation of Revenue by Reportable Segment and Geographic Region (Detail) - USD ($) $ in Thousands	3 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	$ 47,421	$ 51,480
Revenue, % change	(8.00%)
Diagnostics [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	$ 34,791	36,665
Revenue, % change	(5.00%)
Diagnostics [Member] | Americas [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	$ 27,735	30,423
Revenue, % change	(9.00%)
Diagnostics [Member] | EMEA [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	$ 6,500	5,802
Revenue, % change	12.00%
Diagnostics [Member] | ROW [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	$ 556	440
Revenue, % change	26.00%
Life Science [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	$ 12,630	14,815
Revenue, % change	(15.00%)
Life Science [Member] | Americas [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	$ 4,019	4,521
Revenue, % change	(11.00%)
Life Science [Member] | EMEA [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	$ 4,966	7,363
Revenue, % change	(33.00%)
Life Science [Member] | ROW [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	$ 3,645	$ 2,931
Revenue, % change	24.00%

Significant Accounting Polici_6

Significant Accounting Policies - Summary of Disaggregation of Revenue by Product Platform/Type (Detail) - USD ($) $ in Thousands	3 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Segment Reporting Information [Line Items]
Revenue	$ 47,421	$ 51,480
Revenue, % change	(8.00%)
Diagnostics [Member]
Segment Reporting Information [Line Items]
Revenue	$ 34,791	36,665
Revenue, % change	(5.00%)
Diagnostics [Member] | Molecular Assays [Member]
Segment Reporting Information [Line Items]
Revenue	$ 6,887	7,231
Revenue, % change	(5.00%)
Diagnostics [Member] | Immunoassays & Blood Chemistry Assays [Member]
Segment Reporting Information [Line Items]
Revenue	$ 27,904	29,434
Revenue, % change	(5.00%)
Life Science [Member]
Segment Reporting Information [Line Items]
Revenue	$ 12,630	14,815
Revenue, % change	(15.00%)
Life Science [Member] | Molecular Reagents [Member]
Segment Reporting Information [Line Items]
Revenue	$ 5,357	6,615
Revenue, % change	(19.00%)
Life Science [Member] | Immunological Reagents [Member]
Segment Reporting Information [Line Items]
Revenue	$ 7,273	$ 8,200
Revenue, % change	(11.00%)

Significant Accounting Polici_7

Significant Accounting Policies - Summary of Disaggregation of Revenue by Disease State (Detail) - USD ($) $ in Thousands	3 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Segment Reporting Information [Line Items]
Revenue	$ 47,421	$ 51,480
Revenue, % change	(8.00%)
Diagnostics [Member]
Segment Reporting Information [Line Items]
Revenue	$ 34,791	36,665
Revenue, % change	(5.00%)
Diagnostics [Member] | Gastrointestinal Assays [Member]
Segment Reporting Information [Line Items]
Revenue	$ 16,046	18,615
Revenue, % change	(14.00%)
Diagnostics [Member] | Respiratory Illness Assays [Member]
Segment Reporting Information [Line Items]
Revenue	$ 7,749	7,981
Revenue, % change	(3.00%)
Diagnostics [Member] | Blood Chemistry Assays [Member]
Segment Reporting Information [Line Items]
Revenue	$ 5,150	4,430
Revenue, % change	16.00%
Diagnostics [Member] | Other [Member]
Segment Reporting Information [Line Items]
Revenue	$ 5,846	$ 5,639
Revenue, % change	4.00%

Significant Accounting Polici_8

Significant Accounting Policies - Summary of Fair Value, Assets and Liabilities Measured on Recurring Basis (Detail) - USD ($) $ in Thousands	Dec. 31, 2019	Sep. 30, 2019	Jun. 03, 2019
Business Combination, Contingent Consideration, Liability	$ 28,389		$ 27,202
Commitments [Member]
Business Combination, Contingent Consideration, Liability	28,389	$ 27,202
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | Commitments [Member]
Business Combination, Contingent Consideration, Liability	0	0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | Commitments [Member]
Business Combination, Contingent Consideration, Liability	0	0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | Commitments [Member]
Business Combination, Contingent Consideration, Liability	$ 28,389	$ 27,202

Acquisition of Business of Ge_3

Acquisition of Business of GenePOC - Additional Information (Detail) - USD ($)	Jun. 03, 2019	Jun. 30, 2019	Dec. 31, 2019	Sep. 30, 2019	May 24, 2019
Contingent consideration liability	$ 27,202,000		$ 28,389,000
Milestone payable current			13,653,000
Milestone payable due in year two and three			19,736,000	$ 32,202,000
Goodwill			$ 89,958,000	$ 89,241,000
Goodwill Tax Deductable Period			15 years
Financial Performance Targets [Member] | Maximum [Member]
Potential milestone payment			$ 50,000,000
Product Development Milestone A [Member]
Potential milestone payment			$ 10,000,000
Milestone measurement date			Sep. 30, 2020
Product Development Milestone B [Member]
Potential milestone payment			$ 10,000,000
Milestone measurement date			Mar. 31, 2021
Revolving Credit Facility [Member]
Line of Credit Facility, Maximum Borrowing Capacity					$ 125,000,000
GenePOC Inc [Member]
Maximum Business Combination Consideration		$ 120,000,000
Assets acquired liabilities assumed net	77,526,000
Contingent consideration liability	27,202,000
Cash payment to acquire business	50,000,000
Business Combination Closing Payment Holdback	5,000,000
Goodwill	34,582,000
GenePOC Inc [Member] | Financial Performance Targets [Member] | Maximum [Member]
Potential milestone payment			$ 50,000,000
GenePOC Inc [Member] | Revolving Credit Facility [Member]
Line of Credit Facility, Maximum Borrowing Capacity	$ 125,000,000

Acquisition of Business of Ge_4

Acquisition of Business of GenePOC - Schedule Of Assets Acquired And Liabilities (Detail) - USD ($) $ in Thousands	Dec. 31, 2019	Sep. 30, 2019	Jun. 03, 2019
Fair value of assets acquired -
Goodwill	$ 89,958	$ 89,241
Genepoc Inc [Member]
Fair value of assets acquired -
Accounts receivable			$ 57
Inventories			1,511
Other current assets			84
Property, plant and equipment			1,424
Goodwill			34,582
Other intangible assets (estimated useful life):
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets			78,584
Fair value of liabilities assumed -
Accounts payable and accrued expenses			1,058
Total consideration paid (including contingent consideration originally estimated at $27,202)			77,526
Genepoc Inc [Member] | Previously Reported [Member]
Fair value of assets acquired -
Accounts receivable			58
Inventories			1,617
Other current assets			77
Property, plant and equipment			1,520
Goodwill			34,482
Other intangible assets (estimated useful life):
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets			78,584
Fair value of liabilities assumed -
Accounts payable and accrued expenses			1,082
Total consideration paid (including contingent consideration originally estimated at $27,202)			77,502
Genepoc Inc [Member] | Measurement Period Adjustments [Member]
Fair value of assets acquired -
Accounts receivable			(1)
Inventories			(106)
Other current assets			7
Property, plant and equipment			(96)
Goodwill			100
Fair value of liabilities assumed -
Accounts payable and accrued expenses			(24)
Total consideration paid (including contingent consideration originally estimated at $27,202)			24
Genepoc Inc [Member] | Licensing Agreements [Member]
Other intangible assets (estimated useful life):
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill			5,990
Genepoc Inc [Member] | Licensing Agreements [Member] | Previously Reported [Member]
Other intangible assets (estimated useful life):
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill			5,990
Genepoc Inc [Member] | Technology-Based Intangible Assets [Member]
Other intangible assets (estimated useful life):
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill			34,136
Genepoc Inc [Member] | Technology-Based Intangible Assets [Member] | Previously Reported [Member]
Other intangible assets (estimated useful life):
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill			34,040
Genepoc Inc [Member] | Technology-Based Intangible Assets [Member] | Measurement Period Adjustments [Member]
Other intangible assets (estimated useful life):
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill			96
Genepoc Inc [Member] | Government Grants [Member]
Other intangible assets (estimated useful life):
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill			800
Genepoc Inc [Member] | Government Grants [Member] | Previously Reported [Member]
Other intangible assets (estimated useful life):
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill			$ 800

Acquisition of Business of Ge_5

Acquisition of Business of GenePOC - Schedule Of Assets Acquired And Liabilities (Parenthetical) (Detail) - USD ($) $ in Thousands	3 Months Ended
	Dec. 31, 2019	Jun. 03, 2019
Acquired Finite-Lived Intangible Assets [Line Items]
Business Combination, Contingent Consideration, Liability	$ 28,389	$ 27,202
Licensing Agreements [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	10 years
Technology-Based Intangible Assets [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	15 years
Government Grants [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	1 year 3 months 29 days

Acquisition of Business of Ge_6

Acquisition of Business of GenePOC - Consolidated Pro Forma Results Of The Combined Entities (Detail) - Genepoc Inc [Member] - USD ($) $ in Thousands	3 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Business Acquisition, Pro Forma Information [Abstract]
Net Revenues	$ 47,421	$ 51,552
Net Earnings	$ 2,827	$ 4,379

Acquisition of Business of Ge_7

Acquisition of Business of GenePOC - Business Acquisition, Pro Forma Adjustments (Detail) - USD ($) $ in Thousands	3 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Pro forma adjustments:
Expenses related to non-continuing personnel, locations or activities		$ 568
Incremental depreciation and amortization		(876)
Incremental interest costs		(284)
Tax effects of pro forma adjustments		68
Total Adjustments to Net Earnings		(3,727)
GenePOC Inc [Member]
Adjustments to Net Revenues
GenePOC pre-acquisition revenues		72
Adjustments to Net Earnings
GenePOC pre-acquisition net loss		$ (3,203)

Restructuring - Summary of Rest

Restructuring - Summary of Restructuring Costs (Detail) $ in Thousands	3 Months Ended
	Dec. 31, 2019USD ($)
Restructuring Cost and Reserve [Line Items]
Balance at September 30, 2019	$ 1,136
Restructuring charges	316
Reversal of prior period accruals	(41)
Payments	(1,199)
Balance at December 31, 2019	212
Employee Separation and Related Costs [Member]
Restructuring Cost and Reserve [Line Items]
Balance at September 30, 2019	1,010
Restructuring charges	236
Reversal of prior period accruals	(41)
Payments	(1,020)
Balance at December 31, 2019	185
Lease and Other Contract Termination Fees [Member]
Restructuring Cost and Reserve [Line Items]
Balance at September 30, 2019	12
Restructuring charges	80
Payments	(65)
Balance at December 31, 2019	27
Other [Member]
Restructuring Cost and Reserve [Line Items]
Balance at September 30, 2019	114
Payments	(114)
Balance at December 31, 2019

Restructuring - Additional Info

Restructuring - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019
Restructuring Cost and Reserve [Line Items]
Restructuring costs	$ 275
Restructuring Charges Excluding CEO Transition Costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring costs	$ 275	$ 2,839

Cash and Equivalents - Componen

Cash and Equivalents - Components of Cash and Cash Equivalents (Detail) - USD ($) $ in Thousands	Dec. 31, 2019	Sep. 30, 2019	Dec. 31, 2018
Cash and Cash Equivalents [Line Items]
Cash and cash equivalents	$ 68,557	$ 62,397	$ 61,523
Institutional Money Market Funds [Member]
Cash and Cash Equivalents [Line Items]
Cash and cash equivalents	21,010	20,913
Cash [Member]
Cash and Cash Equivalents [Line Items]
Cash and cash equivalents	$ 47,547	$ 41,484

Inventories - Components of Inv

Inventories - Components of Inventories (Detail) - USD ($) $ in Thousands	Dec. 31, 2019	Sep. 30, 2019
Inventory [Line Items]
Raw materials	$ 8,549	$ 7,455
Work-in-process	12,209	11,504
Total	42,827	39,617
Instruments [Member]
Inventory [Line Items]
Finished goods	688	935
Kits and Reagents [Member]
Inventory [Line Items]
Finished goods	$ 21,381	$ 19,723

Leasing Arrangements - Addition

Leasing Arrangements - Additional Information (Detail) $ in Thousands	3 Months Ended
	Dec. 31, 2019USD ($)
Lessee, Lease, Description [Line Items]
Remaining lease term	4 years 8 months 12 days
Leases discount rate	3.70%
Cost of Sales [Member]
Lessee, Lease, Description [Line Items]
Operating lease cost	$ 129
Operating Expense [Member]
Lessee, Lease, Description [Line Items]
Operating lease cost	$ 267

Leasing Arrangements - Schedule

Leasing Arrangements - Schedule Of Supplemental Cash Flow Information Related To The CompanyS Operating Lease Liabilities (Detail) $ in Thousands	3 Months Ended
	Dec. 31, 2019USD ($)
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$ 387

Leasing Arrangements - Schedu_2

Leasing Arrangements - Schedule of maturities of lease liabilities (Detail) - USD ($) $ in Thousands	Dec. 31, 2019	Sep. 30, 2019
Lessee, Lease, Description [Line Items]
Remainder of 2020	$ 1,132
2020		$ 1,528
2021	1,456	1,451
2022	1,310	1,293
2023	967	967
2024	712	712
Thereafter	616	616
Total lease payments	6,193	$ 6,567
Less amount of lease payment representing interest	(380)
Total present value of lease payments	$ 5,813

Intangible Assets- Additional I

Intangible Assets- Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Amortization Of Intangible Assets	$ 1,722	$ 829
2020	5,038
2021	5,491
2022	5,113
2023	5,100
2024	5,096
2025	$ 5,096

Intangible Assets - Summary of

Intangible Assets - Summary of Acquired Intangible Assets Subject to Amortization (Detail) - USD ($) $ in Thousands	Dec. 31, 2019	Sep. 30, 2019
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	$ 96,197	$ 95,775
Accumulated Amortization	37,611	35,532
Manufacturing Technologies, Core Products and Cell Lines [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	56,273	56,193
Accumulated Amortization	16,057	15,096
Tradenames, Licenses and Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	14,596	14,494
Accumulated Amortization	6,566	6,094
Customer Lists, Customer Relationships, and Supply Agreements [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	24,500	24,274
Accumulated Amortization	14,626	14,110
Government Grants [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	828	814
Accumulated Amortization	$ 362	$ 232

Bank Credit Arrangements - Addi

Bank Credit Arrangements - Additional Information (Detail) - USD ($)	May 24, 2019	Dec. 31, 2019	Sep. 30, 2019	May 31, 2019	Mar. 22, 2016
Debt Instrument [Line Items]
Fair value of interest rate swap				$ 563,000
Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Debt instrument effective interest rate		3.96%
Line of credit facility borrowing Capacity	$ 125,000,000
Draws on credit facility		$ 75,824,000	$ 75,824,000
Expiration of credit facility	May 2024
Interest Rate Swap [Member]
Debt Instrument [Line Items]
Interest rate swap balance reflected within other comprehensive income		$ 384,000	$ 461,000
Five - Year Term Loan [Member] | Magellan [Member]
Debt Instrument [Line Items]
Long-term Debt					$ 60,000,000
Long-term Debt, Term					5 years

Reportable Segment and Major _3

Reportable Segment and Major Customers Information - Additional Information (Detail) - Customer Concentration Risk [Member] - Customer	3 Months Ended		12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Sep. 30, 2019
Two Diagnostic Distributor Customers [Member] | Consolidated Accounts Receivable [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Number of major customers	2		2
Concentration risk percentage	21.00%		13.00%
Two Diagnostic Distributor Customers [Member] | Revenues [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Concentration risk percentage	20.00%	24.00%
Two Diagnostic Distributor Customers [Member] | Segment, Third-Party Sales Revenue [Member] | Diagnostics [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Concentration risk percentage	28.00%	34.00%
Two Diagnostic Manufacturing Customers [Member] | Segment, Third-Party Sales Revenue [Member] | Life Science [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Concentration risk percentage	15.00%	28.00%

Reportable Segment and Major _4

Reportable Segment and Major Customers Information - Segment Information (Detail) - USD ($) $ in Thousands	3 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Sep. 30, 2019
Segment Reporting Information [Line Items]
Net revenues	$ 47,421	$ 51,480
Operating income	5,394	10,551
Goodwill	89,958		$ 89,241
Other intangible assets	58,586		60,243
Total assets	338,128		325,478
Restructuring and litigation costs	370	589
Corporate [Member]
Segment Reporting Information [Line Items]
Operating income	(2,087)	(3,391)
Eliminations [Member]
Segment Reporting Information [Line Items]
Operating income	12	27
Total assets	(467)		(83)
Net revenues	(162)	(339)
Operating Segments [Member] | Diagnostics [Member]
Segment Reporting Information [Line Items]
Net revenues	34,791	36,665
Operating income	4,408	8,786
Goodwill	70,415		70,395
Other intangible assets	58,277		59,807
Total assets	266,514		255,169
Net revenues	97	163
Operating Segments [Member] | Life Science [Member]
Segment Reporting Information [Line Items]
Net revenues	12,630	14,815
Operating income	3,061	5,129
Goodwill	19,543		18,846
Other intangible assets	309		436
Total assets	72,081		$ 70,392
Net revenues	$ 65	$ 176

Reportable Segments and Major C

Reportable Segments and Major Concentration Data - Pre-tax Earnings Table (Detail) - USD ($) $ in Thousands	3 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Segment Reporting [Abstract]
Segment operating income	$ 7,481	$ 13,942
Corporate expenses	(2,087)	(3,391)
Interest income	111	149
Interest expense	(767)	(363)
Other, net	(712)	139
EARNINGS BEFORE INCOME TAXES	$ 4,026	$ 10,476

Litigation Matters - Additional

Litigation Matters - Additional information (Detail) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended
	Jul. 09, 2019	Dec. 31, 2019	Dec. 31, 2018
Loss Contingencies [Line Items]
Settlement of Plaintiff Payment	$ 2,100
Litigation costs		$ 320	$ 589
DOJ Subpoena [Member]
Loss Contingencies [Line Items]
Litigation filing date		April 17, 2018
Litigation costs		$ 280	$ 540
Class Action Complaint One [Member]
Loss Contingencies [Line Items]
Litigation filing date		November 15, 2017
Class Action Complaint Two [Member]
Loss Contingencies [Line Items]
Litigation filing date		December 6, 2017
Amended Complaint [Member]
Loss Contingencies [Line Items]
Litigation filing date		April 16, 2018